References
- Kawasaki T. Acute febrile mucocutaneous syndrome with lymphoid involvement with specific desquamation of the fingers and toes in children: Clinical observations of 50 cases (in Japanese). Arerugi 1967;16:178-222.
- Wood LE, Tulloh RM. Kawasaki disease in children. Heart 2009;95;787-92. https://doi.org/10.1136/hrt.2008.143669
- Johnson LL, Dyer R, Hupe DJ. Matrix metalloproteinases. Curr opin Chem Biol 1998;2:466-71. https://doi.org/10.1016/S1367-5931(98)80122-1
- Roy R, Yang J, Moses MA. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J Clin Oncol 2009;27:5287-97. https://doi.org/10.1200/JCO.2009.23.5556
- Zhang B, Ye S, Herrmann SM, Eriksson P, de Maat M, Evans A, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation 1999;99:1788-94. https://doi.org/10.1161/01.CIR.99.14.1788
- Lee YH, Kim TY, Hong YM. Metalloproteinase-3 genotype as a predictor of cardiovascular risk in hypertensive adolescents. Korean Circ J 2009;39:328-4. https://doi.org/10.4070/kcj.2009.39.8.328
- Li YY, Feldman RM, Sun Y, McTiernan CF. Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 1998;98:1728-34. https://doi.org/10.1161/01.CIR.98.17.1728
- Herron GS, Unemori E, Wong M, Rapp JH, Hibbs MH, Stoney RJ. Connective tissue proteinases and inhibitors in abdominal aortic aneurysms involvement of the vasa vasorum in the pathogenesis of aortic aneurysms. Arterioscler Thromb 1991;11:1667-77. https://doi.org/10.1161/01.ATV.11.6.1667
- Hovsepian DM, Ziporin SJ, Sakurai MK, Lee JK, Curci JA, Thomson RW. Elevated plasma levels of matrix metalloproteinase- 9 in patients with abdominal aortic aneurysms: a circulating marker of degenerative aneurysm disease. J Vasc Interv Radiol 2000;11:1345-52. https://doi.org/10.1016/S1051-0443(07)61315-3
- Matsuyama T. Tissue inhibitor of metalloproteinases-1 and matrix metalloproteinase-3 in Japanese healthy children and in Kawasaki disease and their clinical usefulness in juvenile rheumatoid arthritis. Pediatr Int 1999;41:239-45. https://doi.org/10.1046/j.1442-200x.1999.01061.x
- Senzaki H, Masutani S, Kobayashi J, Kobayashi T, Nakano H, Nagasaka H, et al. Circulating matrix metalloproteinases and their inhibitors in patients with Kawasaki disease. Circulation 2001;104;860-3. https://doi.org/10.1161/hc3301.095286
- Gavin PJ, Crawford SE, Shulman ST, Garcia FL, Rowley AH. Systemic arterial expression of matrix metalloproteinases 2 and 9 in acute Kawasaki disease. Arterioscler Thromb Vasc Biol 2003;23:576-81. https://doi.org/10.1161/01.ATV.0000065385.47152.FD
- Zhang Y, McCluskey K, Fujii K, Wahl LM. Differential regulation of monocyte matrix metalloproteinase and TIMP-1 production by TNF-alpha, granulocyte- macrophage CSF, and IL-1 beta through prostaglandin-dependent and -independent mechanisms. J Immunol 1998;161:3071-6.
- Pugin J, Widmer MC, Kossodo S, liang CM, Preas HL Il, Suffredini AF. Human neutrophils secrete gelatinase B in vitro and in vivo in response to endotoxin and proinflammatory mediators. Am J Respir Cell Mol Biol 1999;20:458-64. https://doi.org/10.1165/ajrcmb.20.3.3311
- Yasmin, McEniery CM, Wallace S, Dakham Z, Pulsalkar P, Maki-Petaja K, et al. Matrix metalloproteinase-9 (MMP-9), MMP-2, and serum elastase activity are associated with systolic hypertension and arterial stiffness. Arterioscler Thromb Vasc Biol 2005;25:372.
- Tan J, Hua Q, Xing X, Wen J, Liu R, Yang Z. Impact of the metalloproteinase-9/tissue inhibitor of metalloproteinase-1 system on large arterial stiffness in patients with essential hypertesion. Hypertens Res 2007;30:959-63. https://doi.org/10.1291/hypres.30.959
- Lau AC, Duong TT, Ito S, Yeung RS. Matrix metalloproteinase 9 activity leads to elastin breakdown in an animal model of Kawasaki disease. Arthritis Rheum 2008;58:854-63. https://doi.org/10.1002/art.23225
- Lau AC, Duong TT, Ito S, Wilson GJ, Yeung RS. Inhibition of matrix metalloproteinase-9 activity improves coronary outcome in an animal model of Kawasaki disease. Clin Exp Immunol 2009;157:300-9. https://doi.org/10.1111/j.1365-2249.2009.03949.x
- Lau AC, Duong TT, Ito S, Yeung RS. Intravenous immunoglobulin and salicylate differentially modulate pathogenic processes leading to vascular damage in a model of Kawasaki disease. Arthritis Rheum 2009;60:2131-41. https://doi.org/10.1002/art.24660
- Peng Q, Zhou TF, Chen CH, Jua YM, Liu HM, Hong H, et al. Clinical value of serum matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 for the prediction and early diagnosis of coronary artery lesion in patients with Kawasaki disease. Zhonghua Er Ke Za Zhi 2005;43:676-80.
- Cho AR, Hong YM. Matrix metalloproteinases, tissue inhibitors and cytokines in patients with Kawasaki disease. Korean J Pediatr 2004;47:656-64.
- Takeshita S, Tokutomi T, Kawase H, Nakatani K, Tsujimoto H, Kawamura Y, et al. Elevated serum levels of matrix metalloproteinase- 9 (MMP-9) in Kawasaki disease. Clin Exp Immunol 2001;125:340-4. https://doi.org/10.1046/j.1365-2249.2001.01608.x
- Chua PK, Melish ME, Yu Q, Yanagihara R, Yamamoto KS, Nerurkar VR. Elevated levels of matrix metalloproteinase 9 and tissue inhibitor of metalloproteinase 1 during acute phase of Kawasaki disease. Clin Dign Lab Immunol 2003;10:308-14.
- American Heart Association, Inc. Adapted in part from the Japan Kawasaki Disease Research Committee. Circulation 2001;103:335-6. https://doi.org/10.1161/01.CIR.103.2.335
- Rowley AH, Gonzalez-Crussi F, Gidding SS, Duffy CE, Shulman ST. Incomplete Kawasaki disease with coronary artery involvement. J Pediatr 1987;110:409-13. https://doi.org/10.1016/S0022-3476(87)80503-6
- Kurotobi S, Nagai T, Kawakami N, Sano T. Coronary diameter in normal infants, children and patients with Kawasaki disease. Pediatr Int 2002;44:1-4. https://doi.org/10.1046/j.1442-200X.2002.01508.x
- Holman RC, Curns AT, Belay ED, Steiner CA, Schonberger LB. Kawasaki syndrome hospitalizations in the United States, 1997 and 2000. Pediatrics 2003;112:495-501. https://doi.org/10.1542/peds.112.3.495
- Park YW. Epidemiology of Kawasaki disease in Korea. Korean J Pediatr 2008; 51:452-6. https://doi.org/10.3345/kjp.2008.51.5.452
- Tsuchida S, Yamanaka T, Tsuchida R, Nakamura Y, Yashiro M, Yanagawa H. Epidemiology of infant Kawasaki disease with a report of the youngest neonatal case ever reported in Japan. Acta Pediatr 1996;85:995-7. https://doi.org/10.1111/j.1651-2227.1996.tb14201.x
- Cho EY, Eun BW, Kim NH, Lee JN, Choi EH, Lee HJ, et al. Association between Kawasaki disease and acute respiratory viral infections. Korean J Pediatr 2009;52:1241-8. https://doi.org/10.3345/kjp.2009.52.11.1241
- Onouchi Y, Gunji T, Burns JC, Shimizu C, Newburger JW, Yashiro M, et al. ITPKC functional polymorphism associated with Kawasaki disease susceptibility and formation of coronary artery aneurysms. Nat Genet 2008;40:35-42. https://doi.org/10.1038/ng.2007.59
- Yang JH, Park MH, Shim JY, Jung HL, Park MS, Keum DH. Increased matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 levels in the cerebrospinal fluid from children with aseptic meningitis. J Korean Pediatr Soc 2003;46:548-53.
- Medley TL, Cole TJ, Dart AM, Gatzka CD, Kingwell BA. Matrix metalloproteinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expression. Arterioscler Thromb Vasc Biol 2004;24:1479-84. https://doi.org/10.1161/01.ATV.0000135656.49158.95
- Lin J, Davis HB, Dai Q, Chou YM, Craig T, Hinojosa- Laborde C, et al. Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008;31:1225-31. https://doi.org/10.1291/hypres.31.1225